SR One Capital Management, LP
Follow13F filer, CIK 1910264, Redwood City, CA
SR One Capital Management, LP reported $410,084,894 across 11 holdings for the quarter ended 2024-12-31, in a 13F-HR filed 2025-02-13. Its ten largest share positions make up 98.99% of the portfolio.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-25-002049
- Period
- 2024-12-31
- Reported value
- $410M
- Holdings
- 11
- Top 10 weight
- 98.99%
- New
- 0
- Sold out
- 0
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| KALAadded | +155,279 | $1.08M |
| ORKAadded | +55,000 | $1.07M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
None.
Holdings, Q4 2024
Share positions as resolved from 13F-HR 0000950123-25-002049, largest first. % of portfolio is the value over $410,084,894, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| ACLXARCELLX INC | 2,346,630 | $180M | 43.88% | 0 | Timeline | ||
| SPRYARS PHARMACEUTICALS INC | 4,012,903 | $42.3M | 10.32% | 0 | Timeline | ||
| CRSPCRISPR THERAPEUTICS AG | 1,048,951 | $41.3M | 10.07% | 0 | Timeline | ||
| DSGNDESIGN THERAPEUTICS INC | 6,526,476 | $40.3M | 9.82% | 0 | Timeline | ||
| ZBIOZENAS BIOPHARMA INC | 4,911,539 | $40.2M | 9.81% | 0 | Timeline | ||
| MLYSMINERALYS THERAPEUTICS INC | 2,016,822 | $24.8M | 6.05% | 0 | Timeline | ||
| ALMSALUMIS INC | 1,959,896 | $15.4M | 3.76% | 0 | Timeline | ||
| ORKAORUKA THERAPEUTICS INC | 430,330 | $8.34M | 2.03% | +55,000 | Timeline | ||
| NKTXNKARTA INC | 3,333,333 | $8.3M | 2.02% | 0 | Timeline | ||
| ENGNENGENE HOLDINGS INC | 747,750 | $4.97M | 1.21% | 0 | Timeline | ||
| KALAKALA BIO INC | 598,940 | $4.16M | 1.01% | +155,279 | Timeline |
How Q4 2024 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0000950123-25-002049 | base | 2025-02-13 | acceptance time not in the bulk data set |